Vaccines
Tonix Pharmaceuticals Advances Lyme Disease Prevention with Phase 1 Data and Plans for Phase 2 Study
Tonix Pharmaceuticals reported Phase 1 data for its Lyme disease prevention candidate TNX-4800 and announced plans for an adaptive Phase 2 field study, highlighting the unmet need for prophylactic options in the U.S.
GeoVax Advances Mpox/Smallpox Vaccine Toward Phase 3 Trial Amid Global Supply Concerns
GeoVax Labs is preparing to initiate a pivotal Phase 3 trial for its GEO-MVA vaccine in the second half of 2026, addressing critical global supply constraints for orthopoxvirus vaccines while reporting a reduced net loss of $21.5 million for 2025.
Personalized mRNA Vaccine Shows Promise in Extending Pancreatic Cancer Survival
A personalized mRNA vaccine has demonstrated potential to meaningfully extend survival for pancreatic cancer patients, according to six-year trial results presented at a major oncology conference.
GeoVax Advances Vaccine Programs Amid Global Health Crises Despite Financial Losses
GeoVax Labs reported significant progress in its mpox, COVID-19, and cancer vaccine programs during Q3 2025, positioning the company as a key player in addressing urgent public health needs while navigating financial challenges.
GeoVax Emphasizes Vaccine Innovation and Trust Building on World Immunization Day
GeoVax Labs is advancing next-generation multi-antigen vaccines and U.S. manufacturing capabilities to address declining public confidence in newer vaccines while protecting vulnerable populations.
Soligenix Secures Financial Stability Through 2026 to Advance Rare Disease and Biodefense Pipeline
Soligenix has strengthened its financial position with strategic capital initiatives, providing runway through 2026 to advance multiple late-stage therapeutic and vaccine candidates addressing rare diseases and biodefense needs.
GeoVax to Report Q3 2025 Financial Results and Provide Business Update
GeoVax Labs will report its third quarter 2025 financial results and provide updates on its clinical-stage vaccine and immunotherapy programs, including COVID-19 vaccines for immunocompromised patients and oncology treatments.
GeoVax Vaccine Data Aligns With New IDSA Guidelines for Protecting Immunocompromised Patients
GeoVax's GEO-CM04S1 vaccine demonstrates robust T-cell responses and cross-variant durability in immunocompromised populations, addressing critical gaps identified in new IDSA guidelines that show current COVID-19 vaccines provide only moderate, short-lived protection for vulnerable patients.
Soligenix ThermoVax Technology Addresses Critical Vaccine Stability Challenge in Epidemic Response
Soligenix's development of thermostable vaccines that remain stable at high temperatures could significantly reduce global vaccine wastage and improve deployment in outbreak regions where cold chain infrastructure is limited.
New IDSA Guidelines Highlight Critical Need for Tailored COVID-19 Vaccines for Immunocompromised Population
GeoVax's GEO-CM04S1 vaccine addresses the significant protection gap for over 40 million immunocompromised Americans who experience limited effectiveness from current COVID-19 vaccines, as highlighted by new Infectious Diseases Society of America guidelines.
Study Finds mRNA COVID Vaccine May Enhance Cancer Immunotherapy Effectiveness
New research presented at the European Society for Medical Oncology conference suggests mRNA coronavirus vaccines could potentially boost the effectiveness of cancer immunotherapy treatments.
GeoVax Reports Positive Interim Results for Multi-Antigen COVID-19 Vaccine in Immunocompromised Patients
GeoVax Labs announced promising Phase 2 clinical trial results showing its multi-antigen COVID-19 vaccine candidate demonstrates strong safety and robust T-cell responses in immunocompromised patients, potentially addressing a critical gap in protection for vulnerable populations.
GeoVax Executives Pursue European Partnerships to Advance Vaccine and Cancer Therapy Development
GeoVax Labs is intensifying European partnership efforts to accelerate development of vaccines for mpox, COVID-19, and cancer therapies, addressing critical global health needs.
GeoVax to Present COVID-19 Vaccine Data for Immunocompromised Patients at European Vaccine Congress
GeoVax Labs will present interim safety data and special-population insights for its GEO-CM04S1 COVID-19 vaccine at the World Vaccine Congress Europe 2025, highlighting progress in addressing vaccine needs for immunocompromised patients where current options remain insufficient.
GeoVax CEO to Present at ROTH Healthcare Conference, Highlighting Vaccine and Cancer Therapy Pipeline
GeoVax Labs' participation in the ROTH Healthcare Opportunities Conference provides investors with insights into the company's advancing vaccine and cancer therapy pipeline, including progress on Mpox, COVID-19 vaccines, and oncology treatments.
GeoVax Sponsors 2025 Global Health Equity Summit to Advance Vaccine Access
GeoVax's sponsorship of the Dr. David Satcher Global Health Equity Summit highlights the biotechnology company's commitment to ensuring equitable global access to vaccines and therapies, particularly for immunocompromised and underserved populations.
GeoVax Aligns Vaccine Pipeline with U.S. Global Health Strategy, Emphasizing Pandemic Preparedness
GeoVax Labs supports the new America First Global Health Strategy, highlighting how its vaccine development programs and manufacturing innovations address national security priorities while advancing global health security.
GeoVax Reaffirms Commitment to Vaccine Safety Amid Development of GEO-CM04S1 for Immunocompromised Patients
GeoVax Labs emphasizes its evidence-based approach to vaccine safety and the advancement of GEO-CM04S1, a COVID-19 vaccine designed for vulnerable populations with weakened immune systems who respond poorly to current options.
GeoVax's CM04S1 Vaccine Shows Promise for Immunocompromised Patients in Phase 2 Trials
GeoVax Labs' next-generation COVID-19 vaccine candidate demonstrates superior immune responses in immunocompromised patients compared to mRNA vaccines, potentially addressing critical gaps in current vaccination strategies.
GeoVax's Multi-Antigen COVID-19 Vaccine Shows Superior Immune Response in CLL Patients Compared to mRNA Vaccines
GeoVax's GEO-CM04S1 vaccine demonstrated significantly better immune response in chronic lymphocytic leukemia patients than standard mRNA vaccines, addressing a critical unmet need in immunocompromised populations.
GeoVax's Multi-Antigen COVID-19 Vaccine Shows Strong Immune Response in Immunocompromised Patients
GeoVax Labs' GEO-CM04S1 vaccine demonstrates robust immunity in high-risk patients with blood cancers, potentially addressing a multi-billion dollar market where current vaccines have limited effectiveness.
Maryland Leaders Announce Crime Initiative Amid Federal Tensions and Election Concerns
Maryland officials are implementing a renewed state-city police collaboration to address crime while pushing back against federal election interference attempts and ensuring COVID-19 vaccine availability.
GeoVax's Multi-Antigen COVID-19 Vaccine Shows Promise for Immunocompromised Patients
GeoVax Labs will present clinical data demonstrating that its GEO-CM04S1 vaccine generates cross-variant antibody and robust cellular immune responses in immunocompromised patients with hematologic malignancies, potentially addressing a critical gap in COVID-19 protection for vulnerable populations.
Soligenix Announces Two-Year Stability for Thermostable Ebolavirus Vaccines
Soligenix's ThermoVax platform demonstrates extended vaccine stability at elevated temperatures, potentially revolutionizing global distribution and pandemic preparedness for Ebola and related viruses.
GeoVax Secures Patent for Multi-Antigen COVID-19 Vaccine Technology
GeoVax Labs has obtained a key U.S. patent for its multi-antigen COVID-19 vaccine technology, strengthening its position in developing next-generation vaccines that could provide broader and more durable protection against evolving variants.
GeoVax to Showcase Mpox Vaccine Progress at Emerging Growth Conference
GeoVax Labs, Inc. will present updates on its GEO-MVA Mpox vaccine development at the Emerging Growth Conference, highlighting potential regulatory acceleration and manufacturing advantages.
Soligenix Advances Heat-Stable Ricin Vaccine Amid Global Biothreat Concerns
Soligenix Inc. is progressing with RiVax®, a heat-stable vaccine against ricin toxin, showcasing significant potential in biodefense and public safety.
GeoVax Advocates for MVA-Based Vaccines Following HHS mRNA Vaccine Rollback
GeoVax Labs highlights the advantages of its MVA-based multi-antigen vaccine, GEO-CM04S1, as a solution to the limitations of mRNA vaccines identified by the HHS, emphasizing broader and more durable protection against COVID-19 and other viruses.
GeoVax Advances in Vaccine Development and Immunotherapy with Promising Clinical Data
GeoVax Labs reports significant progress in its vaccine and immunotherapy pipeline, including favorable regulatory guidance for GEO-MVA and robust immune responses from GEO-CM04S1 in CLL patients, highlighting the company's potential to address urgent medical needs.
Global Vaccination Goals Threatened as 14 Million Children Miss Essential Vaccines in 2024
The latest UN data reveals a significant gap in global vaccination efforts, with 14 million children not receiving critical vaccines in 2024, posing a risk to worldwide health targets.